Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Long-Term Investments (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Long-Term Investments for 4 consecutive years, with $2.7 million as the latest value for Q2 2025.

  • On a quarterly basis, Long-Term Investments fell 96.33% to $2.7 million in Q2 2025 year-over-year; TTM through Jun 2025 was $2.7 million, a 96.33% decrease, with the full-year FY2024 number at $30.8 million, down 65.41% from a year prior.
  • Long-Term Investments was $2.7 million for Q2 2025 at Century Therapeutics, down from $20.7 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $144.6 million in Q2 2023 to a low of $2.7 million in Q2 2025.
  • A 4-year average of $65.1 million and a median of $54.9 million in 2022 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: surged 191.07% in 2023, then plummeted 96.33% in 2025.
  • Century Therapeutics' Long-Term Investments stood at $51.9 million in 2022, then soared by 71.82% to $89.1 million in 2023, then crashed by 65.41% to $30.8 million in 2024, then crashed by 91.27% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Long-Term Investments are $2.7 million (Q2 2025), $20.7 million (Q1 2025), and $30.8 million (Q4 2024).